Home » Epiphany: Phase IIb Shingles Trial Yields Positive Results

Epiphany: Phase IIb Shingles Trial Yields Positive Results

November 18, 2009

Epiphany Biosciences announced results from its Phase 2b dose-ranging study of EPB-348 (valomaciclovir) in patients with shingles (herpes zoster) infection.
redOrbit

10Mar
FDA Drug GMP Facility Inspections During the Pandemic
16Mar
Pharmaceutical Naming Regulation: Understanding the Latest Developments
18Mar
Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19
23Mar
Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges
30Mar
Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges
06Apr
Medical Device Cybersecurity: Understand the Latest Developments

Epiphany: Phase IIb Shingles Trial Yields Positive Results

Upcoming Events

FDA Drug GMP Facility Inspections During the Pandemic

Pharmaceutical Naming Regulation: Understanding the Latest Developments

Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

Biological Risk Evaluation and Management for Medical Devices

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

Vetex Medical’s Thrombectomy Catheter Cleared by FDA

Merck Purchases Rights to Debiopharm’s Xevinapant for More Than $1 Billion

Abbott Gets FDA EUA for COVID-19 IgG Antibody Test

In $1.55 Billion Deal, Perrigo Sells Off Generic Drug Business

The Revised ICH E8: A Guide to New Clinical Trial Requirements